Roughly 30% of patients with metastatic prostate cancer and 32% of those with advanced urothelial cancer underwent next-generation sequencing. Most patients with advanced prostate cancer or urothelial ...
Tempus AI's partnerships with NYU Langone and Northwestern Medicine aim to expand genomic testing and data-driven cancer care ...
Treatment preferences between survival and quality of life and their association with clinical outcomes in older adults with advanced cancer. Rates of first NGS relative to the time of death (in pts ...
“Emerging technologies leveraging ctDNA and NGS are increasing our ability to identify cancers in high-risk patients, which was previously beyond reach,” said Dr. Nathan Montgomery, Vice President of ...
The "Canada Next-Generation Sequencing (NGS) Market - A Canada and Regional Analysis: Focus on Application, Technology, Offering, End User, and Regional Analysis - Analysis and Forecast, 2025-2035" ...
FT. MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress ...
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback